Skip to main content

Table 6 Prevalence of hyperkalaemia among subjects taking 1–4 drugs increasing serum potassium level (angiotensin-converting enzyme inhibitors + angiotensin II receptor blockers + aldosterone antagonists + potassium-sparing diuretics + potassium-containing agents)

From: Use of renal risk drugs in a nation-wide Polish older adult population: an analysis of PolSenior database

No. of drugs CC sMDRD
<  60 ml/min ≥ 60 ml/min <  60 ml/min/1.73m2 ≥ 60 ml/min/1.73m2
1; n (%) of subjects with hyperkalaemia 102/669 (15.26)* & 73/952 (7.67) & 73/391 (18.67)# & 102/1230 (8.29)
2; n (%) of subjects with hyperkalaemia 57/258 (22.09)* 22/248 (8.87) 52/180 (28.89)# 27/326 (8.28)
3; n (%) of subjects with hyperkalaemia 14/54 (25.93) 13/51 (25.49) 14/30 (46.67)# 13/75 (17.33)
4; n (%) of subjects with hyperkalaemia 1/1 (100) 0/33 (0) 1/1 (100) 0/3 (0)
  1. *p < 0.05 vs. patients with CC ≥ 60 ml/min
  2. #p < 0.05 vs. patients with sMDRD ≥60 ml/min/1.73m2
  3. &p < 0.05 for chi-square test for trend for number of drugs
  4. sMDRD short Modification of Diet in Renal Disease study equation; CC Creatinine clearance calculated with Cockcroft-Gault equation